Depression is associated with reduced levels of the monoamines in the brain, such as 5-HT. The selective 5-HT and noradrenaline re-uptake inhibitors (SNRIs) are thought to restore the levels of 5-HT and noradrenaline in the synaptic cleft by binding at their re-uptake transporters preventing the re-uptake and subsequent degradation of 5-HT and noradrenaline. This re-uptake blockade leads to the accumulation of monoamines in the synaptic cleft and the concentration returns to within the normal range. Selective 5-HT and noradrenaline re-uptake inhibitors have demonstrated clinical efficacy in the treatment of depression In the presence of the SNRIs, small amounts of 5-HT and noradrenaline continue to be degraded in the synaptic cleft.

Click here: Explore the use of SNRIs in depression treatment

file_download Download in HQ

Related content

grid_view Slide Deck
Major depressive disorder (MDD) – Definitions and Diagnosis

This slide deck offers a comprehensive overview of Major Depressive Disorder (MDD), including its definitions, diagnostic criteria, symptom profiles, clinical course, differential diagnoses, and validated rating tools based on DSM-5-TR and ICD-11 guidelines.

02.07.2025 Depression
grid_view Slide Deck Treatment principles
Major depressive disorder (MDD) – Treatment principles

This slide deck covers the treatment principles of Major Depressive Disorder (MDD).

12.06.2025 Depression
grid_view Slide Deck
Major depressive disorder (MDD) – Course, natural history and prognosis

This slide deck covers the course, natural history, and prognosis of Major depressive disorder (MDD)

27.05.2025 Depression